176 related articles for article (PubMed ID: 35641364)
1. Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison.
de Hemptinne Q; Xaplanteris P; Guédès A; Demeure F; Vandeloo B; Dugauquier C; Picard F; Warne DW; Pilgrim T; Iglesias JF; Bennett J
Cardiovasc Revasc Med; 2022 Oct; 43():28-35. PubMed ID: 35641364
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
[TBL] [Abstract][Full Text] [Related]
3. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
4. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Valgimigli M; Windecker S; Pilgrim T
Int J Cardiol; 2021 Jul; 334():37-41. PubMed ID: 33887341
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
[TBL] [Abstract][Full Text] [Related]
6. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
[TBL] [Abstract][Full Text] [Related]
7. Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.
Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Windecker S; Pilgrim T
Catheter Cardiovasc Interv; 2023 Mar; 101(4):687-700. PubMed ID: 36807456
[TBL] [Abstract][Full Text] [Related]
8. Drug-Eluting Resorbable Magnesium Scaffold Implantation in ST-Segment Elevation Myocardial Infarction: A Pilot Study.
de Hemptinne Q; Picard F; Briki R; Awada A; Silance PG; Dolatabadi D; Debbas N; Unger P
J Invasive Cardiol; 2018 Jun; 30(6):202-206. PubMed ID: 29656279
[TBL] [Abstract][Full Text] [Related]
9. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
Iglesias JF; Roffi M; Losdat S; Muller O; Degrauwe S; Kurz DJ; Haegeli L; Weilenmann D; Kaiser C; Tapponnier M; Cook S; Cuculi F; Heg D; Windecker S; Pilgrim T
Lancet; 2023 Nov; 402(10416):1979-1990. PubMed ID: 37898137
[TBL] [Abstract][Full Text] [Related]
11. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
[TBL] [Abstract][Full Text] [Related]
12. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
Iglesias JF; Muller O; Zaugg S; Roffi M; Kurz DJ; Vuilliomenet A; Weilenmann D; Kaiser C; Tapponnier M; Heg D; Valgimigli M; Eeckhout E; Jüni P; Windecker S; Pilgrim T
EuroIntervention; 2018 Aug; 14(6):692-699. PubMed ID: 29205157
[TBL] [Abstract][Full Text] [Related]
13. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
[TBL] [Abstract][Full Text] [Related]
14. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
16. Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation acute myocardial infarction with two different everolimus-eluting stents: a randomized controlled trial of biodegradable versus durable polymer stents.
Otake H; Ishida M; Nakano S; Higuchi Y; Hibi K; Kuriyama N; Iwasaki M; Kataoka T; Kubo T; Tsujita K; Ashikaga T; Shinke T; Itoh T; Kimura T; Morino Y;
Cardiovasc Interv Ther; 2023 Jan; 38(1):75-85. PubMed ID: 35896895
[TBL] [Abstract][Full Text] [Related]
17. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study.
Brugaletta S; Gori T; Tousek P; Gomez-Lara J; Pinar E; Ortega-Paz L; Schulz E; Kocka V; Münzel T; Cequier À; Buono A; Serruys PW; Sabaté M;
EuroIntervention; 2020 Mar; 15(16):1436-1443. PubMed ID: 31845896
[TBL] [Abstract][Full Text] [Related]
18. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
19. Angioscopic Comparison of Early- and Mid-Term Vascular Responses Following Treatment of ST-Elevation Acute Myocardial Infarction With Biodegradable vs. Durable Polymer Everolimus-Eluting Stents - A Prespecified Subanalysis of the MECHANISM AMI RCT.
Nakatani S; Sotomi Y; Suzuki S; Kobayashi T; Hamanaka Y; Omatsu T; Ishida M; Kakizaki S; Otake H; Morino Y; Higuchi Y;
Circ J; 2023 Apr; 87(5):619-628. PubMed ID: 36418112
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
